The LncRNA-Tumor Immune Microenvironment Nexus: Integrative Insights for Cancer Immunotherapy.
TL;DR
Current discoveries defining the lncRNA-TIME nexus are synthesized and advances in high-throughput sequencing, single-cell transcriptomics, and computational modeling that enable the mapping of these complex networks are highlighted.
Abstract
Long non-coding RNAs (lncRNAs) have emerged as pivotal regulators of tumor-immune interactions, bridging epigenetic, transcriptional, and post-transcriptional control of immune signaling networks. Recent multi-omics analyses reveal that lncRNAs shape the tumor immune microenvironment (TIME) by influencing immune-cell differentiation, activation, and exhaustion, as well as cytokine, chemokine, and immune-checkpoint pathways. Acting through molecular scaffolding, chromatin remodeling, and competing endogenous RNA (ceRNA) mechanisms, lncRNAs orchestrate the recruitment and functional polarization of lymphoid and myeloid populations, thereby dictating the balance between antitumor immunity and immune suppression. Integrative evidence further links specific lncRNA signatures to PD-1/PD-L1 checkpoint regulation, metabolic reprogramming, and therapeutic resistance. Here, we synthesize current discoveries defining the lncRNA-TIME nexus and highlight advances in high-throughput sequencing, single-cell transcriptomics, and computational modeling that enable the mapping of these complex networks. We discuss the translational promise of targeting lncRNAs as biomarkers and therapeutic nodes to enhance immunotherapy efficacy. Collectively, these integrative insights position lncRNAs as critical molecular interfaces connecting tumor genomics with immune regulation and open new avenues for precision immuno-oncology.